The Phase III study is designed to evaluate KD019 compared
to erlotinib in patients with stage IIIB/IV NSCLC who have progressed after
first- or second-line chemotherapy. It incorporates an exploratory analysis
using VeriStrat, a commercially available, blood-based test that is currently
used to help physicians guide treatment for patients with non-small cell lung
cancer. VeriStrat testing will be performed on serum samples from the study to
assess the test's utility in identifying patients with better or worse outcomes
following treatment with KD019. As a multiple TKI with superior potency against
wild-type EGFR, KD019 is designed to improve overall survival compared to
erlotinib.

"We are very pleased to work with Kadmon on this program,"
says Dr. Paul Beresford, Biodesix's vice president of business development and
strategic marketing. "Our successful collaboration may bring a personalized
approach to this exciting new therapy."

Over the past year, Biodesix has forged multiple
partnerships with biopharmaceutical companies to examine VeriStrat's utility
with innovative oncology therapies and to discover novel diagnostic tests.